Crisis of access to opioid addiction treatment
DopesickThe Crisis of access to opioid addiction treatment is the distance between knowing what care can help and being able to obtain it in time, afford it, and continue it. The book traces that distance through individual treatment episodes and Virginia’s uneven service system: a patient might reach detox or rehabilitation, yet still be diverted from continuing medication, blocked by cost, or left waiting for a provider. The result is not simply a shortage of treatment, but a care pathway repeatedly broken at its most consequential transitions.
Effective treatment and interrupted care
The evidence contrasts the outcomes of abstinence-only support with those of medication-assisted treatment (MAT). Fewer than one-quarter of people with heroin addiction who received abstinence-only counseling and support remained abstinent for two or more years. For people receiving counseling, support groups, and medication such as methadone, buprenorphine, or naltrexone, the reported recovery rate was roughly 40 to 60 percent. Anna Lembke noted that outcomes could be better still when people remained in treatment, while emphasizing that good opioid-addiction care was not readily available to most people in the United States.
The central obstacle was therefore not a lack of evidence alone. Programs could favor short-term abstinence even as the evidence supported sustained medication alongside behavioral care and recovery support. National Institute on Drug Abuse director Nora Volkow described the evidence as favoring long-term maintenance, rather than short detoxification programs designed to achieve abstinence. The National Institute on Drug Abuse, the Institute of Medicine, the World Health Organization, and the White House drug czar’s office all supported indefinite, and possibly lifelong, maintenance for opioid-use disorder. Hazelden Betty Ford Foundation, associated with the twenty-eight-day rehabilitation model, had begun offering Suboxone to some patients in 2012; nevertheless, most programs, including the one Jesse Bolstridge attended, remained oriented toward abstinence.
That mismatch shaped Jesse’s care. In January 2013, he entered a ten-week program in Jacksonville that included intensive counseling and medical detox. He briefly received buprenorphine, sold as Suboxone, but was tapered off after three weeks. His mother, Kristi Fernandez, had already incurred a $25,000 debt for the treatment, despite insurance coverage; Jesse paid $25 a week through an automatic deduction from his checking account. The program’s short use of medication reflected a broader controversy over tapering, and its consequences were especially stark beside the evidence for continued maintenance. Even obtaining one course of care left a large bill and no assurance of continuity.
Cost, distance, and the treatment cascade
The book presents access as a sequence of hurdles rather than a single yes-or-no decision: finding a provider, securing a place, meeting financial requirements, entering a program that accepts a patient’s treatment needs, and maintaining care afterward. Tess Henry’s pregnancy made those barriers particularly visible. After leaving jail in June 2015, nearly seven months pregnant, she spent a month with her mother, Patricia, before the family found a private treatment center two hours away that would admit her during the final month of pregnancy. Private insurance covered most of the $20,000 bill, while her father paid the $6,500 deductible from the remainder of Tess’s college-savings fund.
The Life Center of Galax was among the few facilities in Virginia that accepted patients taking medication. Tess received Subutex, a buprenorphine formulation without naloxone that was then recommended for some pregnant patients. Her treatment illustrates how a facility’s medication policy could determine whether a patient had a viable option at all; distance, insurance, and a substantial deductible still determined whether she could take it. The expense of residential treatment also contrasted with the more limited support available after discharge.
Later, buprenorphine helped Tess feel normal, and her insurance paid 80 percent of the medication’s cost. Access to the prescribing doctor remained cash-based: she needed $700 up front and paid $90 to $100 for each follow-up visit, as many as four in a month, to remain monitored and receive medication. Waiting lists compounded the expense. At the time, federal rules limited doctors certified to prescribe MAT to 100 patients each; the cap was raised to 275 later that year. A nominally covered medication could thus remain practically inaccessible when physician appointments carried high upfront costs or were unavailable.
Virginia’s service and insurance gaps
Local capacity was thin even in a region with an urgent need. In Virginia, treatment options in Roanoke consisted of short-term detox and one privately owned facility that accepted insurance or cash, charged around $20,000 for a twenty-eight-day stay, and did not allow maintenance medication. Roanoke’s police chief hoped that Carilion Clinic, the region’s largest employer, with nonprofit hospitals and an addiction-research center, would provide inpatient care. That hoped-for local resource was not yet available, leaving families to navigate distant or costly alternatives.
The state’s refusal to expand Medicaid deepened the gap. After repeated efforts to expand coverage under the Affordable Care Act, Virginia legislators rejected a proposal in June 2014. The book describes the decision as forgoing $6.6 million a day in federal funds and coverage for 400,000 low-income Virginians. In states that expanded Medicaid, the program became a major source of payment for treatment, counseling, and addiction medications. It also covered an additional 1.3 million people with addiction who were not poor enough for Medicaid but could not afford private insurance. Virginia’s policy left more people dependent on limited facilities and out-of-pocket payment.
The effects extended beyond addiction clinics. A fifty-four-year-old teacher in the region had lacked insurance for decades, except when pregnancy made her eligible for Medicaid. Her husband, disabled by a series of strokes after working at Walmart, received Medicare. Because Virginia had not expanded Medicaid, she assembled care through free Remote Area Medical events and visits to the Health Wagon’s mobile unit. She delayed seeing her family doctor, who offered a discounted cash visit for $63, until she was nearly dying. Her circumstances show how the same coverage gap shaped both routine health care and access to treatment: help existed in fragments, but patients had to reach it through precarious arrangements.
Referral efforts and changing capacity
Roanoke’s Hope Initiative tried to make the search for care more navigable. Its volunteers created a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers across the southeastern United States, with contacts arranged according to a patient’s finances and available beds. Volunteers sometimes helped organize outpatient MAT as well, although opinion among them was divided; some objected to treating addiction with another drug despite the supporting evidence. On the second Monday of each month, people could go to the Bradley Free Clinic and, if police found no outstanding warrants, be paired with trained volunteers to troubleshoot their care. Social-service workers could help eligible visitors apply for Medicaid. Each element addressed a different handoff, but the process still depended on provider availability, a person’s eligibility, and the possibility of navigating multiple systems.
Further efforts sought to connect emergency treatment directly to continuing care. Warren Bickel received a $1 million grant for a pilot at the Virginia Tech Carilion Research Institute to streamline transfers from emergency departments to outpatient treatment. The proposed approach would connect people who had overdosed to buprenorphine through Sublocade, a newly approved monthly injection. Yet local capacity remained constrained: the Roanoke Community Services Board had added MAT for twenty-one patients, conditional on their first engaging in counseling, while Carilion still had a three-week wait for outpatient MAT. Bickel argued that a patient who tested positive for additional opioids needed an increased, not reduced, Suboxone dose, illustrating how treatment could be undermined not only by scarcity but also by clinical decisions at follow-up.
In 2017, Hughes Melton helped broaden MAT access in Virginia through the state’s opioid response. He flew weekly between his Suboxone clinic, Highpower, in Lebanon and his Richmond office, and worked with state Medicaid officials to broaden reimbursement and include payment for mandatory counseling and care coordination. Those changes were partly intended to encourage cash-only clinics to accept insurance, including Medicaid. Some clinics eventually did, but recognition of the scale of need, and the spread of practical access into communities, remained slow.
The crisis beyond the clinic door
The book connects access to treatment with the economic conditions surrounding the epidemic. In Martinsville and Henry County, unemployment rose above 20 percent, food-stamp claims more than tripled, and disability rates increased 60.4 percent amid globalization, automation, and coal’s decline. Shannon Monnat described the collapse of work as a structural problem and compared economic distress to kindling, with opiates as the spark. This framing resists reducing the crisis to individual choices: employment, income, insurance, and local services shaped both vulnerability and the possibility of recovery.
The same analysis treats community rebuilding as part of the conditions for sustained recovery. Nancy D. Campbell emphasized the importance of rewarding alternatives to drug use, including work, recreation, and relationships around which people can build their lives. Treatment access in this account is not exhausted by admission to a clinic. It depends on whether continuing care is affordable and available, and whether life outside treatment offers the support and opportunities needed to remain engaged.
Across Jesse Bolstridge’s brief exposure to medication, Tess Henry’s costly search for pregnancy-compatible care, Virginia’s limited treatment capacity, and the Hope Initiative’s referral work, the recurring pattern is a fragile transition from one service to the next. A person may be revived, referred, insured for medication, or accepted for rehabilitation and still encounter a new payment, wait, eligibility rule, or institutional objection. The crisis is defined by those accumulating breaks: evidence-based treatment exists, but the systems that could deliver it often fail to make sustained care reachable.
